newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

BIAFBIAFW
  • bioAffinity Technologies reported 2025 financial results showing a 34% decrease in total revenue to $6.2 million due to the discontinuation of unprofitable pathology services.
  • Revenue from the CyPath® Lung diagnostic test increased 87% year-over-year, driven by a 99% rise in the number of tests performed.
  • Orders for CyPath® Lung rose 67% year-over-year as the physician and clinic ordering network expanded significantly.
  • Operating expenses decreased 9% to $16.7 million following operational streamlining at the Precision Pathology Laboratory Services subsidiary.
  • The company recorded a net loss of $14.9 million for 2025, compared to $9.0 million in 2024, largely due to changes in the fair value of warrants.
  • Cash and cash equivalents increased to $6.5 million at year-end 2025 after raising approximately $16.9 million in gross proceeds from equity transactions.
  • Gordon Downie, MD, PhD, joined as Chief Medical Officer while Roberto Rios, CPA, and John J. Oppenheimer, MD, were appointed to the Board of Directors.
  • The company strengthened its global intellectual property portfolio with new patent allowances in the U.S., Canada, China, and Australia for lung cancer detection methods.
  • 2026 financial outlook forecasts CyPath® Lung unit sales to increase by more than 100% compared to 2025 levels.
  • A longitudinal trial evaluating CyPath® Lung enrolled its first patient in March 2026 with plans to include up to 2,000 patients across federal and private medical centers.
  • A February 2026 collaboration with Brooke Army Medical Center aims to evaluate CyPath® Lung on sputum samples obtained via bronchoscopy suctioning.
  • Research continues on diagnostic tests for asthma and COPD, with patient studies expected to begin in 2026 to guide personalized treatment.
  • Real-world case studies released in 2025 and early 2026 demonstrated the test's ability to detect early-stage lung cancer and support noninvasive surveillance decisions.